Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
About this item
Full title
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2022-09, Vol.387 (9), p.790-798
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
During the 2022 clinical rollout of nirmatrelvir in Israel, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen in patients at highest risk for Covid-19 progression, such as those 65 years of age or older.
Alternative Titles
Full title
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9454652
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9454652
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2204919
